Terms of Reference of the Environmental, Social and Governance Committee of the Board

List of Directors and their Roles and Functions

Terms of reference of the environmental social and governance committee of the board

BLA Accepted in China for Boan Biotech’s Denosumab Injection (BA1102) for the Oncology Indications

Yantai, China, March 21, 2023 —Boan Biotech today announced that the Biologics License Application (BLA) for BA1102 (Denosumab Injection), a biosimilar for the oncology indications, has been accepted...

Voluntary Announcement Acceptance of BLA in China for the Group's Denosumab Injection (BA1102) for the Onocology Indications

Boan Biotech Announces Publication of Phase 1 Clinical Study Results of BA5101 in the Journal of Expert Opinion on Biological Therapy

Recently, the results of the phase 1 clinical study of Dulaglutide Injection (BA5101, formerly coded LY05008) , a biosimilar of Trulicity® solely developed by Boan Biotech, were published in the journ...

Patient Enrollment Completed for BA9101 Phase 3 Clinical Study

Boan Biotech today announced that patient enrollment has been completed for the Phase 3 clinical study (comparative clinical study of efficacy and safety) of BA9101 (Aflibercept Intravitreous Injectio...

Voluntary Announcement Patient Enrollment Completed in the Phase 3 Clinical Study of BA9101 in China

Notice of Board Meeting

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023